N@N

HYF, NBG, FSYS, PDLI, ENH, INCY Are Seasonally Ripe To Go Down In the Next Five Weeks

^{Published on 2011-02-15 15:40:42 - WOPRAI}
 

February 15, 2011 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of MANAGED HI YLD PLUS FUND INC (NYSE:HYF), NATIONAL BANK OF GREECE-ADR (NYSE:NBG), FUEL SYSTEMS SOLUTIONS INC (NASDAQ:FSYS), PDL BIOPHARMA INC (NASDAQ:PDLI), ENDURANCE SPECIALTY HOLDINGS (NYSE:ENH), INCYTE CORP (NASDAQ:INCY) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Down:

     Symbol     Company                             Expected Return     Odds                    By The Following Date
     HYF        MANAGED HI YLD PLUS FUND INC        -5.030 %            70.59% (12 of 17)       Thursday, March 24th 2011
     NBG        NATIONAL BANK OF GREECE-ADR         -5.480 %            63.64% (7 of 11)        Thursday, March 24th 2011
     FSYS       FUEL SYSTEMS SOLUTIONS INC          -17.000 %           88.89% (16 of 18)       Thursday, March 24th 2011
     PDLI       PDL BIOPHARMA INC                   -9.240 %            68.42% (13 of 19)       Tuesday, March 22nd 2011
     ENH        ENDURANCE SPECIALTY HOLDINGS        -5.080 %            71.43% (5 of 7)         Monday, March 21st 2011
     INCY       INCYTE CORP                         -13.710 %           76.47% (13 of 17)       Monday, March 21st 2011

MANAGED HI YLD PLUS FUND INC (NYSE:HYF) - MANAGED HI YLD PL

NATIONAL BANK OF GREECE-ADR (NYSE:NBG) - National Bank of Greece S.A., together with its subsidiaries, provides diversified financial services primarily in Greece. The company involves in retail and commercial banking, global investment management, investment banking, insurance, investment activities, and securities trading operations. It offers time deposits, savings deposits, demand deposits, current accounts, safe deposit boxes, and foreign currency deposits; investment products and securities trading services; consumer loans, personal loans, automobile loans, overdraft facilities, and mortgage loans; trade financing, and debit and credit cards; and ATMs, mobile banking, and Internet banking services. The company also provides financial and investment advisory services, foreign exchange, custody arrangements, trade finance services, private banking, corporate finance advisory services, underwriting, equity and debt financing, project finance, payment services, and mutual funds, as well as bancassurance, including real estate insurance, payment protection insurance, and life and disability insurance; and investment-saving-retirement insurance products. In addition, it offers currency swaps and options, credit lines, letters of credit, guarantees, and shipping finance services. Further, the company engages in the treasury activities, investment banking, and asset management, as well as leasing, factoring, real estate management, and hotel and warehousing businesses. It serves individuals, professionals, small-medium and small sized companies, and corporate customers. The company also has operations in south east Europe, Turkey, and Africa. As of December 31, 2008, it operated 579 branches, 1 private banking unit, 1 unit for financial institutions, and 10 specialized banking units; and 1,466 ATMs in Greece. The company was founded in 1841 and is headquartered in Athens, Greece.

FUEL SYSTEMS SOLUTIONS INC (NASDAQ:FSYS) - Fuel Systems Solutions, Inc. engages in the design, manufacturing, and supply of alternative fuel components and systems for use in the transportation, industrial, and power generation industries. Its components and systems control the pressure and flow of gaseous alternative fuels, such as propane and natural gas used in internal combustion engines. The company offers a range of fuel delivery components, including pressure regulators, fuel injectors, flow control valves, and other components to control the pressure, flow, and/or metering of gaseous fuels; electronic controls comprising solid-state components and proprietary software that monitor and optimize fuel pressure and flow for engine requirements; and gaseous fueled internal combustion engines. It also provides systems integration support to integrate the gaseous fuel storage, fuel delivery, and/or electronic control components and sub-systems; auxiliary power systems for truck and diesel locomotives; and natural gas compressors and refueling systems for light and heavy duty refueling applications. In addition, the company designs, manufactures, assembles, and markets ancillary components for systems operation on alternative fuels, as well as offers engineering and systems integration services. Fuel Systems Solutions, Inc. supplies its products and systems primarily to automobile manufacturers, taxi companies, transit and shuttle bus companies, and delivery fleets through a network of distributors and dealers, as well as through a sales force that develops sales with distributors, original equipment manufacturers, and end-users. Fuel Systems Solutions, Inc. was formerly known as IMPCO Technologies Inc. and changed its name to Fuel Systems Solutions, Inc. in August, 2006. The company was founded in 1958 and is based in New York, New York.

PDL BIOPHARMA INC (NASDAQ:PDLI) - PDL BioPharma Inc., formerly Protein Design Labs, Inc., is a biopharmaceutical company focused on discovering, developing and commercializing therapies for severe or life threatening illnesses. The Company markets and sells products in the acute care hospital setting in the United States and Canada, and receives royalties through licensing agreements with a number of biotechnology and pharmaceutical companies based on its antibody humanization technology platform. The Company's product development pipeline includes six investigational compounds in Phase II or Phase III clinical development for hepatorenal syndrome, inflammation and autoimmune diseases, cardiovascular disorders and cancer. On March 23, 2005, the Company completed the acquisition of all of the outstanding stock of ESP Pharma Holding Company, Inc. (ESP Pharma), a privately held hospital-focused company. It also acquired from Centocor, Inc. (Centocor) the right to manufacture, develop, market and distribute Retavase in the United States and Canada during the year ended December 31, 2005.

Marketed Products

The Company's portfolio of actively marketed products consists of three biopharmaceutical products. Cardene IV is a branded, United States-approved dihydropyridine class calcium channel blocker delivered intravenously that is indicated for short-term treatment of hypertension when oral therapy is not feasible or desirable. Retavase is indicated for use in the management of heart attacks (acute myocardial infarction (AMI)) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI. The Company re-launched Retavase in April 2005, after acquiring it in March 2005.

IV Busulfex, an IV formulation of busulfan, is a chemotherapeutic agent used as part of a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. IV Busulfex provides anti-tumor effect to eradicate residual malignancy, ablation of the bone marrow to make space for the new source of stem cells and to provide immunosuppression to prevent graft rejection. IV Busulfex was launched in Europe by Pierre Fabre Medicament S.A. (Pierre Fabre) and in several Asian countries by Kirin Brewery Company, Limited (Kirin). Both Pierre Fabre and Kirin are the Company's distributors in their territories.

Products in Clinical Development

PDL BioPharma Inc. is engaged in the discovery and development of protein-based therapeutic products, with the majority of its emphasis based upon deriving humanized antibody product candidates employing its platform. The Company has six product candidates in clinical development for various disease indications. Four of these are antibodies and are in clinical development with a near-term emphasis on autoimmune and inflammatory diseases and cancer, specifically inflammatory bowel disease, asthma, multiple sclerosis (MS) and solid tumors. The remaining two product candidates, ularitide and terlipressin, were added to the portfolio through the Company's acquisition of ESP Pharma.

Terlipressin is a synthetic, 12-amino acid peptide (1-triglycyl-8-lysine-vasopressin) derived from the natural hormone lysine-vasopressin. Due to its constrictive activity on vascular and extra-vascular smooth muscle cells (V-1 agonist), it reduces blood flow in the splanchnic area, and thereby lowers portal blood pressure. Terlipressin is in Phase III clinical development for the treatment of type 1 hepatorenal syndrome.

Under an agreement with Orphan Therapeutics, PDL BioPharma Inc. holds marketing, sales and distribution rights for terlipressin in the United States and Canada. Orphan Therapeutics holds the investigational new drug (IND) application for terlipressin and is conducting the Phase III clinical trial in the United States and Europe. The ongoing clinical study, conducted by Orphan Therapeutics, is a double-blind, placebo-controlled Phase III trial of terlipressin in patients with type 1 hepatorenal

ENDURANCE SPECIALTY HOLDINGS (NYSE:ENH) - Endurance Specialty Holdings Ltd., through its subsidiaries, engages in underwriting specialty lines of personal and commercial property and casualty insurance and reinsurance worldwide. Its Insurance segment offers property insurance of a commercial nature; casualty insurance for a range of industry groups; and healthcare liability line focusing on excess hospital medical professional liability insurance; and workers compensation insurance. This segment also provides agriculture insurance covering traditional multiple peril crop insurance, crop hail, livestock risk protection, and other agriculture risk management products; and professional lines insurance products, including directors and officers liability, errors and omissions, employment practices liability, environmental liability, and pension trust liability insurance. The companys Reinsurance segment provides casualty reinsurance for reinsuring third party liability exposures from ceding companies, such as automobile liability, professional liability, directors and officers liability, umbrella liability, and workers compensation; property reinsurance for individual property insurance policies; and catastrophe reinsurance focusing on catastrophic perils for ceding companies. This segment also offers agriculture reinsurance for reinsuring risks associated with the production of food and fiber; aerospace reinsurance covering hull, aircraft liability, and aircraft products; marine reinsurance of bluewater hull, brownwater hull, and cargo; surety reinsurance for contract and commercial surety, as well as for the fidelity line of business; and traditional treaty, proportional, and aggregate stop loss reinsurance for primary insurance companies writing multiple peril, hail, and named peril covers. The company markets its products primarily through insurance and reinsurance brokers. Endurance Specialty Holdings Ltd. was founded in 2001 and is based in Pembroke, Bermuda.

INCYTE CORP (NASDAQ:INCY) - Incyte Corporation focuses on the discovery and development of proprietary small molecule drugs for hematologic and oncology indications, and for chronic inflammatory and autoimmune diseases. Its product pipe line includes INCB18424, which is in Phase III clinical trial for myelofibrosis; Phase II trial for polycythemia vera/essential thrombocythemia; Phase I/II trial to treat other hematologic tumors; and Phase IIb trail for the treatment of psoriasis. The companys portfolio also includes INCB28050, a Phase II clinical trial product for rheumatoid arthritis; INCB28060, a Phase I product for solid cancers; INCB7839, a Phase II product for breast cancer; INCB24360, an IND cleared product for oncology; and INCB13739, a Phase IIb product to treat type 2 diabetes. It has a collaborative research and license agreements with Pfizer Inc.; Novartis International Pharmaceutical Ltd.; and Eli Lilly and Company. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641